Search Results 41-50 of 21270 for Inhibition

  1. Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors - Mayo Clinic

    To exploit the dependence of tumors on glutamine, CB-839, a potent and selective inhibitor of the first enzyme in glutamine utilization, glutaminase, will be ...

  2. Impact Of Aromatase Inhibitor Therapy On Glucose Homeostasis And Diabetes Risk - Mayo Clinic

    This study assesses the effect of hormone directed treatment for breast cancer or ductal carcinoma in situ (DCIS) on glucose metabolism. Participation ...

  3. Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors - Mayo Clinic

    The purpose of part one of this study is to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and safety profile of Q901 monotherapy ...

  4. Proton Pump Inhibitors Decrease Diversity in Gut Microbiome, Increase Risk for Complications - Mayo Clinic News Network

    “Evidence has been mounting for years that long-term use of proton pump inhibitors poses increased risks for a variety of associated complications, but we have ...

  5. MDM2 Inhibitor AMG-232 and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma - Mayo Clinic

    The purpose of this phase Ib trial studies the side effects of MDM2 inhibitor AMG-232 and radiation therapy in treating patients with soft tissue sarcoma. MDM2 ...

  6. A Study Of The Pan-KRAS Inhibitor LY4066434 In Participants With KRAS Mutant Solid Tumors - Mayo Clinic

    A Study Of The Pan-KRAS Inhibitor LY4066434 In Participants With KRAS Mutant Solid Tumors · Overview · Participation eligibility · Participating Mayo Clinic ...

  7. Novel HSF1 Pathway Inhibitor NXP800 In Patients with Advanced Cholangiocarcinoma - Mayo Clinic

    About this study. The purpose of this trial is to determine the maximum tolerated dose (MTD)/recommended Phase 2 dose for NXP800.

  8. A Study of the Effect of Ileal Bile Acid Transporter Inhibitor for Functional Constipation - Mayo Clinic

    The purpose of this study is to evaluate the effects of A3309 on gastric, intestinal and colon transit in patients who have functional constipation.

  9. Study to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies - Mayo Clinic

    Study to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition Fusion ...

  10. Cancer Biology and Translational Research - SCD1 is a Novel Molecular Target in Human Carcinomas

    ... inhibitors that are being developed for cancer clinical trials ... Genetic and molecular targeting of SCD1 activity results in tumor-specific inhibition of cell ...